Entropy Technologies’s Ginkgo Bioworks DNA Stock Holding History

Entropy Technologies’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$66.6K	Buy	+10,865	New	+$90.4K	﹤0.01%	856

Other funds holding DNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.18B AUM 27.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Entropy Technologies's DNA Position: Q1 2026 in Review

Entropy Technologies opened a new position in Ginkgo Bioworks (DNA) in Q1 2026: 10,865 shares worth $66.6K. The stake represents ﹤0.01% of the portfolio and ranks #856 among its holdings.

174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

Entropy Technologies held 10,865 shares of Ginkgo Bioworks worth $66.6K as of Q1 2026.
Ginkgo Bioworks was a new Entropy Technologies position in Q1 2026.
Ginkgo Bioworks made up ﹤0.01% of Entropy Technologies's portfolio in Q1 2026, its #856 holding.
174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Entropy Technologies's 13F filing for Q1 2026, filed 14 May 2026.